Latest News on CYRX

Financial News Based On Company


Advertisement
Advertisement

Two funds hold the shares behind a reported 4.8% stake in Cryoport (CYRX).

https://www.stocktitan.net/sec-filings/CYRX/schedule-13g-a-cryoport-inc-amended-passive-investment-disclosure-5ce62e0ff786.html
Cadian Capital Management, LP, along with Cadian Capital Management GP, LLC and Eric Bannasch, reported a beneficial ownership of 2,418,947 common shares of Cryoport, Inc. (CYRX), representing approximately 4.8% of outstanding shares as of September 30, 2026. These shares are directly held by Cadian Master Fund L.P. and Cadian Opportunities Master Fund LP. Cadian Capital Management, LP exercises exclusive voting and investment power over these shares through investment management agreements.

Form 4 Cryoport Inc: Daniel M. Hancock (Director) For: 9 November

https://ca.investing.com/news/stock-market-news/form-4-cryoport-inc-daniel-m-hancock-director-for-9-november-93CH-4960744
The article reports on a Form 4 filing for Cryoport Inc., indicating that Daniel M. Hancock, a Director, made a transaction on November 9th. The report is published by Investing.com.

Form 4 Cryoport Inc: Daniel M. Hancock (Director) For: 9 November By Investing.com

https://in.investing.com/news/stock-market-news/form-4-cryoport-inc-daniel-m-hancock-director-for-9-november-93CH-5706815
This article reports on a Form 4 filing for Cryoport Inc., indicating that Daniel M. Hancock, a Director, made a transaction on November 9th. The filing provides insight into insider trading activity for Cryoport Inc. (CYRX).

Cryoport director Daniel Hancock sells $1.5 million in stock By Investing.com

https://ca.investing.com/news/stock-market-news/cryoport-director-daniel-hancock-sells-15-million-in-stock-93CH-4960716
Cryoport director Daniel M. Hancock sold 74,379 shares of common stock for approximately $1.5 million on November 9, 2026, as part of a pre-arranged trading plan. On the same day, he acquired an equal number of shares through stock option exercises worth about $737,192. This comes after Cryoport's stock saw significant gains, although InvestingPro analysis suggests it is currently overvalued.

CryoPort Inc (CKX.SG) stock price, news, quote and history

https://uk.finance.yahoo.com/quote/CKX.SG/earnings-calls/
This article provides an overview of CryoPort Inc (CKX.SG) stock performance and financial data. It includes current stock price, historical data, key financial metrics, and recent news. The stock is currently trading at 17.20 EUR, down 2.82%, with significant year-to-date and 1-year returns, though it shows a decline over a 5-year period.
Advertisement

CryoPort Up Nearly 20%, On Track for Highest Close Since July 2023 -- Data Talk

https://www.moomoo.com/news/post/1003861057/cryoport-up-nearly-20-on-track-for-highest-close-since
CryoPort (CYRX) stock surged almost 20% during Wednesday's trading session, reaching its highest closing price since July 2023. The significant increase is attributed to the company reporting strong third-quarter results that surpassed analyst expectations. This positive performance has led to a notable uptick in investor confidence.

Cryoport (CYRX) director exercises options and sells 74,379 shares under an automatic trading plan.

https://www.stocktitan.net/sec-filings/CYRX/form-4-cryoport-inc-insider-trading-activity-10e0234e75d9.html
Daniel M. Hancock, a director of Cryoport, Inc. (CYRX), exercised options for 74,379 common shares at various strike prices and subsequently sold all 74,379 shares at a weighted average price of $20.207 per share. These transactions, which occurred on November 9, 2026, were conducted automatically under a pre-adopted trading plan from May 27, 2026. After these transactions, Hancock holds 69,052 common shares and 20,549 stock options.

Form 4 Cryoport Inc: Daniel M. Hancock (Director) For: 9 November

https://ng.investing.com/news/stock-market-news/form-4-cryoport-inc-daniel-m-hancock-director-for-9-november-93CH-2804856
This article reports on a Form 4 filing for Cryoport Inc., detailing insider transactions by Director Daniel M. Hancock related to November 9th. These filings are crucial for investors tracking insider activity, as they can provide insights into a company's financial health and future prospects. The report highlights the specific date of the transaction as November 9th.

CryoPort (NASDAQ:CYRX) Director Sells $1,503,199.59 in Stock

https://www.marketbeat.com/instant-alerts/insider-cryoport-nasdaq-cyrx-director-sells-150319959-in-stock-2026-11-12/
CryoPort Director Daniel Hancock sold 74,379 shares of CYRX stock on November 9th for over $1.5 million, significantly reducing his stake. This transaction was conducted under a pre-arranged Rule 10b5-1 trading plan. The company recently reported a quarterly EPS miss but exceeded revenue expectations, with analysts holding a "Moderate Buy" consensus rating and an average price target of $21.69.

Form 4 Cryoport Inc: Mark W. Sawicki (Chief Scientific Officer) For: 10 November

https://ca.investing.com/news/stock-market-news/form-4-cryoport-inc-mark-w-sawicki-chief-scientific-officer-for-10-november-93CH-4954914
This article reports on a Form 4 filing for Cryoport Inc., specifically detailing insider transactions by Mark W. Sawicki, the Chief Scientific Officer. The filing pertains to activities that occurred on November 10.
Advertisement

CryoPort (NASDAQ:CYRX) Insider Sells $199,300.00 in Stock

https://www.marketbeat.com/instant-alerts/insider-cryoport-nasdaq-cyrx-insider-sells-19930000-in-stock-2026-11-12/
CryoPort (NASDAQ:CYRX) insider Mark Sawicki sold 10,000 shares of the company's stock for $199,300, reducing his ownership by 9.77%. This transaction comes as the company reported a quarterly loss of $0.25 per share, missing analyst expectations, despite revenue exceeding forecasts. Analysts currently hold a "Moderate Buy" consensus rating for CryoPort, with an average price target of $21.69.

Cryoport (CYRX) scientific chief directly holds 92,356 shares after selling 10,000.

https://www.stocktitan.net/sec-filings/CYRX/form-4-cryoport-inc-insider-trading-activity-427d92643c09.html
Mark W. Sawicki, Chief Scientific Officer of Cryoport, Inc. (CYRX), sold 10,000 shares of common stock on November 10, 2026, at a weighted average price of $19.9261 per share. After this transaction, Sawicki directly holds 92,356 shares. The sale occurred in multiple transactions with prices ranging from $19.50 to $20.27.

An officer proposes selling 10,000 Cryoport (CYRX) shares.

https://www.stocktitan.net/sec-filings/CYRX/144-cryoport-inc-sec-filing-332e6a3a61fe.html
Cryoport officer Mark Sawicki has filed a Form 144 proposing to sell 10,000 common shares of Cryoport, Inc. (CYRX), valued at approximately $199,261. The proposed sale date is November 10, 2026, and the shares were acquired through restricted stock vesting under a registered plan. Morgan Stanley Smith Barney LLC is listed as the broker for this transaction.

Cryoport stock reaches 52-week high at 20.56 USD By Investing.com

https://ca.investing.com/news/stock-market-news/cryoport-stock-reaches-52week-high-at-2056-usd-93CH-4947452
Cryoport Inc. (CYRX) has achieved a new 52-week high of $20.56, reflecting a 140% appreciation over the past year and strong recent momentum. Despite this surge, InvestingPro analysis suggests the stock may be overvalued. The company recently reported a 14% revenue increase in Q3 2026 and raised its full-year revenue guidance, leading Needham to increase its price target to $28.

93,646 CryoPort, Inc. $CYRX Shares Sold by CenterBook Partners LP

https://www.marketbeat.com/instant-alerts/filing-93646-cryoport-inc-cyrx-shares-sold-by-centerbook-partners-lp-2026-11-10/
CenterBook Partners LP significantly reduced its stake in CryoPort, Inc. (NASDAQ:CYRX) by selling 93,646 shares, leaving them with 77,944 shares valued at $1,356,000. Other institutional investors also adjusted their positions, and hedge funds collectively own 92.90% of the company's stock. CryoPort's stock performance and recent analyst ratings are also detailed in the article.
Advertisement

CryoPort (NASDAQ:CYRX) Stock Price Breaks Above 50 Day Moving Average on Disappointing Earnings

https://www.marketbeat.com/instant-alerts/price-cryoport-nasdaq-cyrx-stock-price-breaks-above-50-day-moving-average-on-disappointing-earnings-2026-11-06/
CryoPort's stock (NASDAQ:CYRX) rose by 19% and surpassed its 50-day moving average despite reporting a quarterly loss of $0.25 per share, missing consensus estimates. The company's revenue, however, increased 14% year-over-year to $50.22 million, beating expectations, and it also raised its full-year 2026 revenue outlook to $197 million–$199 million. Analyst ratings remain positive, with an average price target of $21.69, suggesting optimism despite the earnings shortfall.

Needham raises CryoPort stock price target to $28 on revenue beat

https://in.investing.com/news/stock-market-news/needham-raises-cryoport-stock-price-target-to-28-on-revenue-beat-93CH-5686272
Needham has increased its price target for CryoPort (NASDAQ:CYRX) shares to $28 from $19, maintaining a Buy rating, following the company's strong third-quarter 2026 revenue performance, which surpassed consensus estimates. The firm highlighted CryoPort's 12% revenue growth over the last twelve months and raised full-year 2026 revenue guidance, citing momentum in its Services segment. Despite the stock appearing overvalued by InvestingPro, analysts anticipate further upside in 2027 as the company continues to focus on growth investments and operational efficiency.

Cryoport, Inc. (CYRX) Raises 2026 Revenue Guidance to $197M–$199M

https://www.tradingview.com/news/tradingview:48c9e176646d5:0-cryoport-inc-cyrx-raises-2026-revenue-guidance-to-197m-199m/
Cryoport (CYRX) reported strong Q3 2026 results with $50.2M in revenue and $1.1M in adjusted EBITDA, alongside a 20% year-over-year increase in commercial CGT revenue. The company raised its full-year 2026 revenue guidance to $197M–$199M, indicating continued growth and progress towards profitability, especially following its 2025 divestiture of CRYOPDP.

CryoPort Q3 2026 Earnings Call Transcript

https://www.benzinga.com/news/26/11/62959611/cryoport-q3-2026-earnings-call-transcript
CryoPort (NASDAQ: CYRX) reported strong third-quarter 2026 results with $50.2 million in revenue, a 14% year-over-year increase, driven by a 20% growth in commercial cell and gene therapy revenue. The company raised its full-year 2026 revenue outlook to $197 million to $199 million and achieved its second consecutive quarter of positive adjusted EBITDA, reaching $1.1 million. CryoPort also expanded its bioservices capabilities in Paris and Santa Ana and received ISO certifications for its Global Supply Chain Center in Paris, highlighting its leadership in the cell and gene therapy ecosystem.

Cryoport Inc earnings missed by $0.07, revenue topped estimates

https://www.investing.com/news/earnings/cryoport-inc-earnings-missed-by-007-revenue-topped-estimates-5005845
Cryoport Inc (NASDAQ: CYRX) reported third-quarter EPS of $-0.25, missing analyst estimates by $0.07, despite revenue of $50.22M topping the consensus estimate of $48.69M. The company's stock has seen a significant increase, up 6.15% in the last three months and 92.68% in the last 12 months. InvestingPro assesses Cryoport Inc's financial health as "good performance".
Advertisement

Earnings Preview: Cryoport to Report Financial Results Post-market on November 05

https://www.moomoo.com/news/post/1003076441/earnings-preview-cryoport-to-report-financial-results-post-market-on
Cryoport (NASDAQ: CYRX) is scheduled to announce its financial results post-market on November 05. The company's last earnings report on August 10 showed an EPS increase of 42.86% year-over-year, beating analyst estimates by $0.10. Analysts currently project Cryoport to report an EPS of -$0.23 for the upcoming quarter.

CryoPort, Inc. Revenue Breakdown – BSESOF:CKX

https://www.tradingview.com/symbols/BSESOF-CKX/financials-revenue/
CryoPort, Inc. (CKX) generated 150.00 million EUR in revenue last year, with its Life Sciences Services segment contributing the most at 86.02 million EUR. The Americas region was the largest contributor to revenue, accounting for 111.76 million EUR. This financial data indicates a slight decrease in overall revenue compared to the previous year.

ETFs Investing in CryoPort, Inc. Stocks

https://www.tradingview.com/symbols/BSESOF-CKX/etfs/
This article lists various Exchange Traded Funds (ETFs) that hold CryoPort, Inc. (CKX) stocks. The provided table details each fund's market value, weight of CKX, issuer, management style, focus, expense ratio, assets under management (AUM), price, percentage change, relative volume, and 3-year NAV total return. The ETFs shown are primarily passive funds focusing on small-cap or large-cap segments, with several from BlackRock, Deutsche Bank AG, The Vanguard Group, and Invesco among others.

Total debt per share of CryoPort, Inc. – BSESOF:CKX

https://www.tradingview.com/symbols/BSESOF-CKX/financials-statistics-and-ratios/total-debt-per-share/
The article, published by TradingView, focuses on the total debt per share of CryoPort, Inc. (CKX BSESOF). It provides a financial overview for the company, indicating that the market was closed with no trades at the time of publication. The content appears to be a stub or a placeholder for detailed financial data.

CryoPort, Inc. Revenue Breakdown – BSESOF:CKX

https://www.tradingview.com/symbols/BSESOF-CKX/financials-segments/
CryoPort, Inc. (CKX) generated 150.00 million EUR in revenue last year, with its Life Sciences Services segment contributing 86.02 million EUR. The Americas region was the largest contributor, accounting for 111.76 million EUR. This represents a slight decrease from the previous year's total revenue of 151.61 million EUR and Americas contribution of 122.07 million EUR.
Advertisement

CryoPort Inc (CKX.SG) stock major holders - Yahoo Finance

https://sg.finance.yahoo.com/quote/CKX.SG/holders/
This Yahoo Finance page provides information on CryoPort Inc (CKX.SG) stock's major holders, including breakdowns of shares held by insiders and institutions. It also displays the current stock price and market performance for various global indices and cryptocurrencies.

CryoPort, Inc. Estimates – NASDAQ:CYRX

https://www.tradingview.com/symbols/NASDAQ-CYRX/financials-estimates/
This article from TradingView provides an overview of CryoPort, Inc. (NASDAQ:CYRX) financial estimates. It highlights access to reported financial data and analyst estimates across various financial statements, allowing users to compare actual results with average, high, and low estimates and visualize trends over time. The page serves as a financial data portal for the company's stock.

After its results come out Nov. 5, Cryoport will take questions from investors

https://www.stocktitan.net/news/CYRX/cryoport-to-report-third-quarter-2026-financial-results-on-november-bkgucfvhteqv.html
Cryoport (NASDAQ: CYRX) announced it will report its third-quarter 2026 financial results on Thursday, November 5, 2026, after U.S. markets close. The company will also issue a document detailing operational developments and strategic initiatives at 4:05 p.m. ET, followed by a 5:00 p.m. ET conference call for a questions and answers session with investors. A slide deck and a replay of the call will be made available on the company's investor relations website.

Cryoport to Report Third Quarter 2026 Financial Results on November 5, 2026

https://www.tradingview.com/news/prnewswire:4dc67a728ac39:0-cryoport-to-report-third-quarter-2026-financial-results-on-november-5-2026/
Cryoport, Inc. (Nasdaq: CYRX) announced it will report its third-quarter 2026 financial results on Thursday, November 5, 2026, after U.S. markets close. The company will also issue a "Cryoport Third Quarter 2026 in Review" document and host a questions and answers conference call at 5:00 p.m. ET to discuss the results.

Cryoport to Report Third Quarter 2026 Financial Results on November 5, 2026

https://finance.yahoo.com/healthcare/articles/cryoport-report-third-quarter-2026-120000145.html
Cryoport, Inc. announced it will report its financial results for the third quarter ended September 30, 2026, on Thursday, November 5, 2026, after U.S. markets close. The company will also issue a "Cryoport Third Quarter 2026 in Review" document and host a questions and answers conference call at 5:00 p.m. ET on the same day.
Advertisement

BTIG raises target to USD 26 for Cryoport stock

https://www.ad-hoc-news.de/boerse/news/nebenwerte/btig-raises-target-to-usd-26-for-cryoport-stock/70377454
BTIG has increased its price target for Cryoport (CYRX) stock from USD 25.00 to USD 26.00, maintaining a Buy rating. This adjustment follows meetings with company executives and a site visit, with the firm anticipating revenue growth and positive EBITDA driven by Cryoport's planned expansion with new facilities in Santa Ana, California, and Paris, France, in the second half of 2026. Despite a negative trailing P/E ratio, the new target suggests a significant upside compared to the current Nasdaq price.

Cryoport Expands with BioServices Offering in Paris

https://www.contractpharma.com/breaking-news/cryoport-expands-with-bioservices-offering-in-paris/
Cryoport is expanding its Paris Global Supply Chain Center (GSCC) to include BioServices, aiming to enhance support for advanced therapy medicinal products (ATMPs) in Europe. This expansion will integrate biostorage, custom kit production, packaging, labeling, and Qualified Person (QP) services, complementing existing French BioServices Centers. The new offering focuses on improving operational efficiency for clinical and commercial programs by providing comprehensive supply chain solutions at every development stage.

CryoPort, Inc. $CYRX Shares Sold by Assenagon Asset Management S.A.

https://www.marketbeat.com/instant-alerts/filing-cryoport-inc-cyrx-shares-sold-by-assenagon-asset-management-sa-2026-10-19/
Assenagon Asset Management S.A. reduced its stake in CryoPort, Inc. (NASDAQ:CYRX) by 19.3% in the third quarter, selling 222,830 shares but retaining a significant holding valued at $16.17 million. Despite missing earnings per share estimates, CryoPort's revenue exceeded expectations, and analysts maintain a "Moderate Buy" consensus rating with an average price target of $19.33. The company, which provides temperature-controlled supply chain solutions for life sciences, continues to operate with negative margins, with a CEO insider sale also noted.

Cryoport stock faces estimated November 3 earnings report

https://www.ad-hoc-news.de/boerse/news/nebenwerte/cryoport-stock-faces-estimated-november-3-earnings-report/70349852
Cryoport (CYRX) is scheduled to release its next earnings report on November 3, 2026, after market close, with analysts estimating a consensus earnings per share of minus USD 0.19 and revenue of USD 48.69 million for the third quarter of 2026. The company's second-quarter revenue reached USD 48.97 million, and its stock closed at USD 16.84 on October 16, 2026, down 1.35 percent, with a market capitalization of USD 852.9 million. Cryoport, which provides temperature-controlled logistics for life sciences, has seen its stock rise 75.40 percent year-to-date.

BTIG raises target for Cryoport stock to USD 26.00

https://www.ad-hoc-news.de/boerse/news/nebenwerte/btig-raises-target-for-cryoport-stock-to-usd-26-00/70331221
BTIG has increased its price target for Cryoport (CYRX) stock to USD 26.00 from USD 25.00, maintaining a Buy rating. This new target represents a 55.32% upside from its current Nasdaq price of USD 16.74. Cryoport, which provides temperature-controlled logistics for life sciences, has a market capitalization of USD 847.7 million and a negative trailing P/E, indicating that future earnings execution will be key to meeting this target.
Advertisement

Cryoport Insiders Sold US$3.4m Of Shares Suggesting Hesitancy

https://www.moomoo.com/news/post/1001035373/cryoport-insiders-sold-us-3-4m-of-shares-suggesting-hesitancy
This article analyzes recent insider selling at Cryoport, where insiders sold US$3.4 million worth of shares over the past year. While some buying also occurred, the significant selling, particularly by CEO Jerrell Shelton, might suggest that insiders believe the stock is fully valued. This activity is considered a factor to observe when evaluating the company's future prospects.

BTIG raises CryoPort stock price target to $26 on facility expansion

https://ng.investing.com/news/stock-market-news/btig-raises-cryoport-stock-price-target-to-26-on-facility-expansion-93CH-2733221
BTIG has increased its price target for CryoPort (NASDAQ: CYRX) shares to $26 from $25, maintaining a Buy rating, following meetings with the company's CFO and IR Head, and a site visit to their bio-logistics facility. The firm anticipates CryoPort will achieve revenue growth and positive EBITDA in the second half of 2026, driven by new facility openings and innovative solutions like the Fusion freezer. Despite an optimistic outlook and significant stock return, InvestingPro analysis suggests the company is currently overvalued and analysts do not expect profitability this year.

CryoPort Q2 2026 Earnings Call Transcript

https://www.benzinga.com/news/26/10/62317614/cryoport-q2-2026-earnings-call-transcript
CryoPort (NASDAQ: CYRX) reported strong Q2 2026 results with $49 million in revenue, driven by a 15% growth in Life Science Services and a 9% increase in commercial cell and gene therapy support. The company achieved a positive adjusted EBITDA of $400,000, marking progress towards profitability, and reaffirmed its full-year revenue guidance of $192 to $196 million. Operational highlights included expanding IntegriCell cryopreservation services and launching new products, with strategic developments in China and the adoption of AI to enhance efficiency.

BTIG raises CryoPort stock price target to $26 on facility expansion By Investing.com

https://za.investing.com/news/stock-market-news/btig-raises-cryoport-stock-price-target-to-26-on-facility-expansion-93CH-4501432
BTIG has increased its price target for CryoPort (NASDAQ:CYRX) shares to $26 from $25, maintaining a Buy rating, following meetings with investors and a site visit to the company's bio-logistics facility. The firm anticipates CryoPort will achieve revenue growth and positive EBITDA in the second half of 2026, driven by new facility openings and innovative solutions like the Fusion freezer. Despite the optimistic outlook and significant stock returns, InvestingPro analysis suggests the company is currently overvalued and analysts do not expect profitability this year.

BTIG raises CryoPort stock price target to $26 on facility expansion

https://ca.investing.com/news/stock-market-news/btig-raises-cryoport-stock-price-target-to-26-on-facility-expansion-93CH-4877601
BTIG has increased its price target for CryoPort (NASDAQ: CYRX) shares to $26 from $25, maintaining a Buy rating, following investor meetings and a site visit to the company's bio-logistics facility. The firm anticipates CryoPort will achieve revenue growth and positive EBITDA in the second half of 2026, driven by facility expansions in Santa Ana and Paris, new technology like the Fusion freezer, and high-revenue Commercial solutions. Despite the stock's strong performance over the past year, InvestingPro analysis suggests it is currently overvalued, with analysts not expecting profitability this year.
Advertisement

CryoPort, Inc. (NASDAQ:CYRX) Stock Has Consensus Price Target of $18.38 According to Brokerages

https://www.marketbeat.com/instant-alerts/consensus-cryoport-inc-nasdaq-cyrx-stock-has-consensus-price-target-of-1838-according-to-brokerages-2026-10-09/
Nine brokerages covering CryoPort, Inc. (NASDAQ:CYRX) have issued a "Moderate Buy" consensus recommendation, with an average 1-year price target of $18.38, compared to its recent opening price of $16.90. The company reported slightly missed earnings estimates but exceeded revenue forecasts in its latest quarter and remains unprofitable. CEO Jerrell Shelton recently sold 28,800 shares, while institutional investors hold a significant 92.9% stake in the life sciences logistics company.

Technical Reactions to CYRX Trends in Macro Strategies

https://news.stocktradersdaily.com/news_release/98/Technical_Reactions_to_CYRX_Trends_in_Macro_Strategies_100726103601_1791383761.html
This article provides a technical analysis of Cryoport Inc. (NASDAQ: CYRX) trends using AI models. It highlights strong sentiment supporting an overweight bias, an exceptional risk-reward setup, and offers distinct trading strategies including Position Trading, Momentum Breakout, and Risk Hedging. The analysis also includes multi-timeframe signal strengths and support/resistance levels.

Cryoport stock fell 1.87 percent near its 52-week high

https://www.ad-hoc-news.de/boerse/news/nebenwerte/cryoport-stock-fell-1-87-percent-near-its-52-week-high/70246473
Cryoport stock (CYRX) closed at USD 17.80 on October 6, 2026, experiencing a 1.87% drop but remaining near its 52-week high of USD 18.36. Despite exceeding revenue expectations for Q2 2026 with USD 48.97 million, the company reported a wider-than-expected EPS loss of USD 0.20. Analysts maintain a "Moderate Buy" rating with an average target price of USD 18.38, indicating limited upside from the current price.

Guggenheim raises target for Cryoport stock from USD 16.00 to USD 19.00

https://www.ad-hoc-news.de/boerse/news/nebenwerte/guggenheim-raises-target-for-cryoport-stock-from-usd-16-00-to-usd-19-00/70239596
Guggenheim has increased its price target for Cryoport (CYRX) stock from USD 16.00 to USD 19.00, maintaining a Buy rating. This adjustment follows Cryoport's strong second-quarter 2026 revenue growth of 8.00 percent to USD 49.0 million and improved adjusted EBITDA. The company also reaffirmed its full-year 2026 revenue guidance of USD 192 million to USD 196 million, emphasizing its focus on execution and cash generation as it expands its temperature-controlled supply-chain network.

CYRX Maintains Rating by Guggenheim -- Price Target Raised to $1

https://www.gurufocus.com/news/9105821/cyrx-maintains-rating-by-guggenheim-price-target-raised-to-1900
Guggenheim maintained its 'Buy' rating for CryoPort (CYRX) and raised its price target from $16.00 to $19.00, indicating confidence in the company's growth potential within the life sciences supply chain sector. Despite the positive analyst rating, CryoPort is considered significantly overvalued by GuruFocus, with a GF Value™ of $9.62 against a current price of $17.39, suggesting a lack of margin of safety for investors. Insider selling activity and a low profitability rank also advise caution, even as the company shows strong growth potential and momentum.
Advertisement

Guggenheim Maintains Cryoport(CYRX.US) With Buy Rating, Raises Target Price to $19

https://www.moomoo.com/news/post/1000512778/guggenheim-maintains-cryoport-cyrxus-with-buy-rating-raises-target-price
Guggenheim has reiterated its Buy rating for Cryoport (CYRX.US) and increased the price target to $19. This updated target suggests a potential upside for the stock.

Cryoport shares jump 82% YTD on strong cell and gene therapy pipeline and profitability rebound

https://pluang.com/en/news-feed/cryoprt-pipeline-terapi-sel-dan-gen-kuat
Cryoport (CYRX) stock has surged 82% year-to-date due to strong growth in cell and gene therapy commercialization and a robust pipeline. The company achieved adjusted EBITDA profitability in Q2 2026, supported by Life Science Services growth and positive operating cash flow. Management expects five new therapy approvals in 2026 and a 15% increase in Phase 3 trials, while maintaining a net cash position despite potential FDA rejections and biotech funding slowdowns.

Cryoport stock trades near its 52-week high after revenue beat

https://www.ad-hoc-news.de/boerse/news/nebenwerte/cryoport-stock-trades-near-its-52-week-high-after-revenue-beat/70176566
Cryoport (CYRX) stock is trading near its 52-week high after the company reported Q2 2026 revenue of $48.97 million, surpassing analyst estimates. Despite beating revenue expectations, the company missed its adjusted EPS forecast. Analysts have a "Moderate Buy" consensus, with BTIG Research reiterating a "Buy" rating and a target price significantly above the current market price.

Cryoport stock gains 1.08 percent as revenue remains central

https://www.ad-hoc-news.de/boerse/news/nebenwerte/cryoport-stock-gains-1-08-percent-as-revenue-remains-central/70159302
Cryoport's stock (CYRX) rose by 1.08% to USD 17.81 on September 22, 2026, driven by its role in temperature-controlled logistics for the life sciences sector. The company's financial performance is closely tied to biopharmaceutical development and clinical supply chains, which can lead to uneven quarterly results. Investors are advised to consider period-specific operating figures to accurately assess Cryoport's profitability beyond daily stock movements.

BTIG Remains a Buy on CryoPort (CYRX)

https://www.theglobeandmail.com/investing/markets/stocks/CYRX/pressreleases/4693312/btig-remains-a-buy-on-cryoport-cyrx/
BTIG analyst David Larsen maintained a Buy rating on CryoPort (CYRX) with a price target of $25.00, following the company's latest earnings report. CryoPort reported a quarterly revenue of $48.97 million and a GAAP net loss of $8.26 million, showing revenue growth compared to the previous year. The company has a Strong Buy analyst consensus with a price target consensus of $20.20, with several firms recently raising their price targets.
Advertisement
Advertisement
Advertisement
Advertisement

Sign Up free to view live trades and discussion forum to make more informed financial decisions. No credit card is required for sign up!
View Daily Trades
Join Discussion

Advertisement
Advertisement
Advertisement
Advertisement